Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. Therma Bright Inc. serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Часто задаваемые вопросы
В каком секторе работает THERMA BRIGHT INC. (JNX)?
THERMA BRIGHT INC. относится к сектору Энергетика.
Какова текущая цена акций THERMA BRIGHT INC. (JNX)?
По последним данным, цена акций THERMA BRIGHT INC. составляет 0,02 €, предыдущее закрытие — 0,02 €.
Выплачивает ли THERMA BRIGHT INC. (JNX) дивиденды?
Нет, THERMA BRIGHT INC. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у THERMA BRIGHT INC. (JNX)?
У компании THERMA BRIGHT INC. бета 3.209, что свидетельствует о крайне высокой волатильности по сравнению с рынком